ArticleBreast cancer research and treatment2022

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).

Paul Jank et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.